Myeloid colony formation by BM cells from ANXA2-deficient recipients with CML was reduced (Supplementary Fig. 5D), and survival of secondary WT recipients of BM, but not spleen cells from ANXA2-deficient donors with CML was significantly prolonged (Supplementary Fig. 5E). Here, ANXA2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.